A detailed history of Rhumbline Advisers transactions in Alector, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 114,004 shares of ALEC stock, worth $449,175. This represents 0.0% of its overall portfolio holdings.

Number of Shares
114,004
Previous 109,924 3.71%
Holding current value
$449,175
Previous $499,000 6.61%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.34 - $6.58 $17,707 - $26,846
4,080 Added 3.71%
114,004 $532,000
Q2 2024

Aug 01, 2024

BUY
$4.19 - $6.23 $77,087 - $114,619
18,398 Added 20.1%
109,924 $499,000
Q1 2024

May 09, 2024

BUY
$5.69 - $8.08 $22,350 - $31,738
3,928 Added 4.48%
91,526 $550,000
Q4 2023

Feb 08, 2024

SELL
$3.77 - $8.39 $312 - $696
-83 Reduced 0.09%
87,598 $699,000
Q3 2023

Nov 09, 2023

SELL
$5.2 - $8.77 $15,246 - $25,713
-2,932 Reduced 3.24%
87,681 $568,000
Q2 2023

Aug 08, 2023

BUY
$5.86 - $7.93 $45,596 - $61,703
7,781 Added 9.39%
90,613 $544,000
Q1 2023

May 11, 2023

SELL
$5.85 - $9.84 $2,749 - $4,624
-470 Reduced 0.56%
82,832 $513,000
Q4 2022

Feb 14, 2023

BUY
$6.88 - $9.55 $29,129 - $40,434
4,234 Added 5.35%
83,302 $769,000
Q3 2022

Nov 10, 2022

BUY
$8.19 - $13.2 $30,810 - $49,658
3,762 Added 5.0%
79,068 $748,000
Q2 2022

Aug 11, 2022

BUY
$7.65 - $14.24 $105,830 - $196,996
13,834 Added 22.5%
75,306 $765,000
Q1 2022

May 12, 2022

BUY
$13.02 - $20.78 $22,824 - $36,427
1,753 Added 2.94%
61,472 $876,000
Q4 2021

Feb 10, 2022

SELL
$19.35 - $25.54 $17,531 - $23,139
-906 Reduced 1.49%
59,719 $1.23 Million
Q3 2021

Nov 12, 2021

BUY
$21.65 - $39.49 $55,164 - $100,620
2,548 Added 4.39%
60,625 $1.38 Million
Q2 2021

Aug 05, 2021

BUY
$15.5 - $22.48 $34,813 - $50,490
2,246 Added 4.02%
58,077 $1.21 Million
Q1 2021

May 06, 2021

SELL
$14.84 - $22.23 $59,374 - $88,942
-4,001 Reduced 6.69%
55,831 $1.12 Million
Q4 2020

Feb 10, 2021

BUY
$9.4 - $16.7 $26,508 - $47,094
2,820 Added 4.95%
59,832 $905,000
Q3 2020

Nov 12, 2020

SELL
$10.54 - $24.96 $99,550 - $235,747
-9,445 Reduced 14.21%
57,012 $601,000
Q2 2020

Aug 13, 2020

BUY
$21.87 - $33.11 $494,786 - $749,080
22,624 Added 51.61%
66,457 $1.62 Million
Q1 2020

May 06, 2020

BUY
$16.25 - $35.28 $177,060 - $384,410
10,896 Added 33.08%
43,833 $1.06 Million
Q4 2019

Feb 05, 2020

BUY
$14.17 - $20.3 $15,700 - $22,492
1,108 Added 3.48%
32,937 $568,000
Q3 2019

Oct 23, 2019

BUY
$14.42 - $22.2 $313,144 - $482,095
21,716 Added 214.73%
31,829 $459,000
Q2 2019

Aug 14, 2019

BUY
$16.26 - $26.42 $164,437 - $267,185
10,113 New
10,113 $192,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $325M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.